About Coalesce
Coalesce is a company based in Cambridge (United Kingdom) founded in 2009 by Dave Ahern was acquired by Sandoz in March 2022. The company has 19 employees as of April 30, 2020. Coalesce operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
- Headquarter Cambridge, United Kingdom
- Employees 19 as on 30 Apr, 2020
- Founders Dave Ahern
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Coalesce Product Development Limited
- Date of Incorporation 29 May, 2009
- Jurisdiction LONDON
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Coalesce
Detailed funding history for Coalesce
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Coalesce
Coalesce has secured backing from 1 investor. Prominent investors backing the company include Sandoz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Generic and biosimilar pharmaceuticals are developed and distributed globally.
|
Locked | Locked | Locked |
Investor details for Coalesce
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Coalesce
Investment portfolio details for Coalesce
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Coalesce
Detailed financials for Coalesce
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Coalesce Comparisons
Peer comparison for Coalesce
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Coalesce
Coalesce operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small-molecule drugs
|
|
| Locked | Locked | Locked |
Intranasal delivery technology for CNS diseases is developed.
|
|
| Locked | Locked | Locked |
Developer of products for the treatment of acute and intermittent conditions
|
|
| Locked | Locked | Locked |
Developer of smart devices for nasal drug delivery
|
|
| Locked | Locked | Locked |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Therapeutics for cardiopulmonary diseases are developed using inhaled therapies.
|
Detailed competitors of Coalesce
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Coalesce
Complete news archive for Coalesce
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Coalesce
Coalesce was founded in 2009.
Coalesce is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Dave Ahern is the current CEO of Coalesce. They have also founded this company.
As of Apr 30, 2020, the latest employee count at Coalesce is 19.
Coalesce was founded in 2009 in Cambridge, United Kingdom, and operates in the medical devices sector. Inhalation devices such as pressurized metered dose inhalers, breath-actuated inhalers, and pre-metered dry powder inhalers are developed by the company. Each device features a substitutable user interface. Focus is placed on innovative delivery systems for respiratory treatments, with operations centered in the UK.
Coalesce's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.
Coalesce has 1 investor. Key investors include Sandoz.